CG Oncology, trading under the symbol NASDAQ:CGON, is a biopharmaceutical company focused on developing innovative cancer therapies. The company is making strides in the oncology sector, particularly with its work on bladder cancer treatments. CGON's competitors include other biotech firms working on similar cancer therapies, but its recent developments have set it apart.
On January 9, 2026, Morgan Stanley set a price target of $93 for CGON, while the stock was trading at $54.20. This suggests a potential increase of about 71.59%. The stock's current price reflects a significant rise of 29.26%, with a change of $12.27, indicating strong market interest.
CG Oncology has received a "Strong Buy" rating due to its pipeline progress and upcoming catalysts in 2026. The company completed the rolling Biologics License Application (BLA) for cretostimogene, targeting high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). A potential FDA acceptance is a key near-term catalyst, as highlighted by the company's recent developments.
The early completion of enrollment in the phase 3 PIVOT-006 trial for intermediate-risk NMIBC has accelerated the timeline for topline data to the first half of 2026. This positions CG Oncology for a potential first FDA approval in this segment, which could significantly impact its market position and stock value.
CGON's market capitalization is approximately $4.06 billion, with a trading volume of 6,958,295 shares on the NASDAQ exchange. The stock has fluctuated between a low of $43.25 and a high of $57.40 today, with a 52-week range of $14.80 to $57.40, reflecting its volatile yet promising nature.
